Mereo BioPharma Group plc (MREO): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of MREO were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Mereo BioPharma Group
From the latest filingsOverall: about as much buying as selling. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MREO
57 funds and institutions reported MREO shares worth $18M at the end of Q2 2026, about 7% of the company. The largest holder is Rubric Capital Management LP with 1.9%.
Funds and institutions (13F) 7%Everyone else 93%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Rubric Capital Management LP | 15.31M | 1.92% | $4.9M | No change |
| 683 Capital Management, LLC | 11.78M | 1.48% | $3.7M | -2% |
| Bank of America Corp | 8.20M | 1.03% | $2.6M | No change |
| Defilade Capital Management, L.P. | 7.56M | 0.95% | $2.4M | No change |
| Newtyn Management, LLC | 3.00M | 0.38% | $953K | -58% |
| Tejara Capital Ltd | 2.04M | 0.26% | $647K | No change |
| UBS Group AG | 1.45M | 0.18% | $460K | -3% |
| Two Sigma Investments, LP | 1.32M | 0.17% | $419K | +602% |
| EcoR1 Capital, LLC | 1.00M | 0.13% | $318K | -93% |
| Jane Street Group, LLC | 774,944 | 0.10% | $246K | +454% |
| Ishara Investments LP | 768,750 | 0.10% | $244K | New |
| Wealthspire Advisors, LLC | 765,000 | 0.10% | $243K | -4% |
| Citadel Advisors LLC | 444,158 | 0.06% | $141K | New |
| Rangeley Capital, LLC | 329,200 | 0.04% | $105K | No change |
| Susquehanna International Group, LLP | 213,270 | 0.03% | $67.8K | +9% |
| Marshall Wace, LLP | 179,884 | 0.02% | $57.6K | -74% |
| XTX Topco Ltd | 174,481 | 0.02% | $55.4K | +107% |
| Group One Trading LLC | 167,515 | 0.02% | $53.2K | -50% |
| State Street Corp | 134,772 | 0.02% | $42.8K | +1% |
| Nomura Holdings Inc | 104,361 | 0.01% | $33.2K | New |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No MREO insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MREO short interest
Low short interest. 0.4% of MREO shares are sold short: about 1 share in 238. Over the last 12 reports the number of shares short went down 41%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.35M MREO shares were sold short, 0.4% of the shares outstanding, up 3.7% from the report before. At the average daily volume of 477,903 shares, buying them all back would take about 7.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.35M | 0.42% | +4% | 477,903 | 7.0 |
| Oct 15, 2026 | 3.23M | 0.40% | +21% | 1.22M | 2.6 |
| Sep 30, 2026 | 2.68M | 0.34% | -13% | 2.14M | 1.2 |
| Sep 15, 2026 | 3.08M | 0.39% | -18% | 1.57M | 2.0 |
| Aug 31, 2026 | 3.76M | 0.47% | -13% | 1.10M | 3.4 |
| Aug 14, 2026 | 4.32M | 0.54% | +26% | 17.70M | 1.0 |
| Jul 31, 2026 | 3.41M | 0.43% | -3% | 1.02M | 3.4 |
| Jul 15, 2026 | 3.54M | 0.44% | -40% | 1.10M | 3.2 |
| Jun 30, 2026 | 5.88M | 0.74% | +10% | 1.85M | 3.2 |
| Jun 15, 2026 | 5.35M | 0.67% | -34% | 3.45M | 1.6 |
| May 29, 2026 | 8.16M | 1.02% | +44% | 11.05M | 1.0 |
| May 15, 2026 | 5.68M | 0.71% | -13% | 1.81M | 3.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Mereo BioPharma Group company events
Mereo BioPharma Group filed 12 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Aug 19, 2026ListingAs previously disclosed, on February 17, 2026, Mereo BioPharma Group plc received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that it no longer met the requirement to maintain a minimum bid price of $1.00 per share for continued listing on… Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Aug 11, 2026AgreementMereo BioPharma Group plc entered into an Option and License Agreement with Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company, for the U.S. commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease. Filing
- May 14, 2026VoteReported shareholder vote results. Filing
- May 12, 2026ResultsAmended an earlier report. Released financial results. Filing
- May 12, 2026DealCompleted a purchase or sale of a business or assets. Filing
- Mar 27, 2026LeadershipDr. Annalisa Jenkins informed Mereo BioPharma plc. Filing
- Mar 19, 2026ResultsReleased financial results. Filing
- Feb 17, 2026ListingMereo BioPharma Group plc received a letter from the Listings Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that its American Depositary Shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required for continued… Filing
- Jan 12, 2026AnnouncementThe Company updated its previous cash runway guidance. Filing
- Dec 29, 2025AnnouncementThe Company announced the results from the Phase 3 Orbit and Cosmic studies evaluating setrusumab (UX143) in pediatric and young adult patients with osteogenesis imperfecta (OI). Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Mereo BioPharma Group financials
Famous investors that hold MREO
2 of the 50 well-known investors we track reported holding MREO in their latest 13F filing. The largest position is Jim Simons's, worth $64.4K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 160,118 | $64.4K | 0.0% | +207% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 42,646 | $17.1K | 0.0% | -90% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named MREO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 28, 2026 | BANK OF AMERICA CORP /DE/ | 13G/A | 3.4% |
| Oct 28, 2026 | BANK OF AMERICA CORP /DE/ | 13G/A | 3.4% |
Questions about Mereo BioPharma Group plc (MREO) stock
Who owns the most MREO stock?
The largest reported owner of Mereo BioPharma Group plc (MREO) is Rubric Capital Management LP, with 1.9% of the company. In total, 57 funds and institutions reported holding MREO at the end of Q2 2026, together about 7% of the shares. See the largest owners.
Are MREO insiders buying or selling?
No MREO insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in MREO?
As of Oct 30, 2026, 3.35M MREO shares were sold short, 0.4% of the shares outstanding, up 3.7% from the report before. At the average daily volume of 477,903 shares, buying them all back would take about 7.0 trading days (days to cover). See the history.
Which famous investors hold MREO?
2 of the 50 well-known investors we track reported MREO in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $64.4K. See all holders.
Executive pay
Mereo BioPharma Group's chief executive was paid a total of $2.7M for the year ended Dec 31, 2025, down 14% from $3.2M the year before. In the last 12 months, Mereo BioPharma Group's executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.